title: High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction.
abstract: OBJECTIVE
  We examined whether antibodies against peptides 45 and 210 of apoB-100 are related to myocardial infarction (MI) and severity of coronary atherosclerosis.
  
  
  RESULTS
  Three hundred and eighty-seven survivors of a first MI (aged <60 years) and 387 sex- and age-matched controls were characterized in detail. IgG and IgM autoantibodies against native and malondialdehyde (MDA)-modified peptides 45 and 210 of apoB-100 (amino acids 661-680 and 3136-3155) were quantified in plasma and quantitative coronary angiography was performed in 243 patients. Post-infarction patients had significantly lower IgG against the native peptide 210 (IgG-p210(nat)) and higher IgM against the MDA-modified peptide 210 (IgM-p210(MDA)) compared with controls, whereas no differences were found for other antibodies. Plasma concentrations of IgG-p210(nat), but not IgM-p210(MDA), were independently and inversely related to the degree of coronary atherosclerosis in patients. In multiple logistic regression analysis (including established risk indicators), MI risk was 0.55 (95%CI: 0.37-0.81) for individuals in the IgG-p210(nat) upper quartile compared with the remaining individuals.
  
  
  CONCLUSIONS
  Circulating IgG antibodies against the native peptide 210 of apoB-100 are inversely related to the severity of coronary atherosclerosis and associated with lower risk of MI. Epitope 210 of apoB-100 emerges as a target for immunization against atherosclerosis in humans.
authors.affiliation: Department of Medicine, Atherosclerosis Research Unit, Solna Karolinska Institutet, Stockholm, Sweden. per.sjogren@pubcare.uu.se
authors.forename: Per
authors.initials: P
authors.lastname: Sjögren
authors.forename: Gunilla N
authors.initials: GN
authors.lastname: Fredrikson
authors.forename: Ann
authors.initials: A
authors.lastname: Samnegard
authors.forename: Carl-Göran
authors.initials: CG
authors.lastname: Ericsson
authors.forename: John
authors.initials: J
authors.lastname: Ohrvik
authors.forename: Rachel M
authors.initials: RM
authors.lastname: Fisher
authors.forename: Jan
authors.initials: J
authors.lastname: Nilsson
authors.forename: Anders
authors.initials: A
authors.lastname: Hamsten
mesh_terms: D053299:Apolipoprotein B-100 / Q000097:blood / Q000276:immunology*; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D017023:Coronary Angiography / Q000379:methods; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000276:immunology*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D007075:Immunoglobulin M / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000276:immunology*; D010455:Peptides / Q000097:blood / Q000276:immunology*; D012307:Risk Factors; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
chemical_list: D053299:Apolipoprotein B-100; D001323:Autoantibodies; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D010455:Peptides